Fig. 3: Alterations in serum ALT, AST, GGT, and ALP levels following treatment with ZSP1601 in the NASH patients. | Nature Communications

Fig. 3: Alterations in serum ALT, AST, GGT, and ALP levels following treatment with ZSP1601 in the NASH patients.

From: ZSP1601, a novel pan-phosphodiesterase inhibitor for the treatment of NAFLD, A randomized, placebo-controlled phase Ib/IIa trial

Fig. 3: Alterations in serum ALT, AST, GGT, and ALP levels following treatment with ZSP1601 in the NASH patients.The alternative text for this image may have been generated using AI.

Time courses for changes from baseline in levels of ALT (a), AST (b), GGT (c), and ALP (d). Data are plotted as mean ± standard deviation (SD). Different groups are indicated in color (placebo, blue; 50 mg QD, brown; 50 mg BID, gray; 100 mg BID, black). Source data are provided as a Source Data file.

Back to article page